|Videos|September 22, 2022
Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Clinical Applications and the Future of Remote Endovascular Procedures
2
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5